Marek David C 4
4 · Axsome Therapeutics, Inc. · Filed Oct 15, 2019
Insider Transaction Report
Form 4
Marek David C
Chief Commercial Officer
Transactions
- Award
Employee Stock Option (Right to Buy)
2019-10-10+25,813→ 25,813 totalExercise: $17.61Exp: 2029-10-09→ Common Stock (25,813 underlying)
Footnotes (1)
- [F1]The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on October 10, 2023; provided, that the vesting of the option will be accelerated such that 100% of the option will become fully vested upon the achievement of certain clinical, operational, and/or other milestones (approved by the compensation committee) prior to, on, or about December 31, 2019.